Evidence map›Paper›PMID 41908680›Full record

ArticleCrohn's & colitis 3602026

Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study.

Vipul Jairath, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, Bruce E Sands, Fumihito Hirai, Toshifumi Hibi, Edward V Loftus, Raymond K Cross, Marijana Protic, Lai Shan Chan and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02891226 (A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02891226 phase2completednot on this map

A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)

TypeinterventionalSponsorEli Lilly and CompanyRan2016 to 2021Enrolled191ConditionsCrohn's DiseaseArmsMirikizumab, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vipul JairathDepartment of Medicine, Division of Gastroenterology, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0002-1092-0033
Theresa Hunter GibbleImmunology, Eli Lilly and Company, Indianapolis, IN, USA.ORCID https://orcid.org/0000-0001-8412-9175
Laurent Peyrin-BirouletDepartment of Gastroenterology, University Hospital of Nancy, Nancy, France.ORCID https://orcid.org/0000-0003-2536-6618
Bruce E SandsDivision of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID https://orcid.org/0000-0001-5762-5042
Fumihito HiraiDepartment of Gastroenterology, Fukuoka University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-5493-5675
Toshifumi HibiCenter for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Edward V LoftusDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Raymond K CrossInflammatory Bowel Disease Program, University of Maryland School of Medicine, Maryland, MD, USA.
Marijana ProticImmunology, Eli Lilly and Company, Indianapolis, IN, USA.
Lai Shan ChanImmunology, Eli Lilly and Company, Indianapolis, IN, USA.
Nathan MorrisImmunology, Eli Lilly and Company, Indianapolis, IN, USA.
Kristina TraxlerImmunology, Eli Lilly and Company, Indianapolis, IN, USA.
David T RubinInflammatory Bowel Disease Centre, University of Chicago Medicine, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mirikizumab is an anti-IL23p19 antibody that has shown efficacy in treating moderately to severely active Crohn's disease in a phase 2 study. We studied mirikizumab's impact on quality of life in these patients. Methods: Patients ( Results: At week 12, all mirikizumab groups had improved quality of life and patient-reported outcome scores compared to placebo. These improvements were sustained through week 52 and week 104. Conclusions: Treatment with mirikizumab was associated with significantly improved quality of life and patient-reported disease severity sustained through week 104 in patients with moderately-to-severely active Crohn's disease in this phase 2 study (NCT02891226).

Indexed as

Crohn’s diseasemirikizumabquality of life

Identifiers

PMID41908680
PMCPMC13017000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.